Press Releases InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement of C$250,000 July 19, 2016 Read More » InMed Announces Appointment of Eric A. Adams as CEO, President and Director June 16, 2016 Read More » InMed Announces Appointment of William J. Garner, M.D. to its Board of Directors June 13, 2016 Read More » InMed Updates Progress of its Epidermolysis Bullosa Program May 18, 2016 Read More » InMed Pharmaceuticals Provides Strategic Update on its Business Plans, Announces Planned Executive and Board Departures May 4, 2016 Read More » InMed Announces Update on Biosynthesis Project February 16, 2016 Read More » InMed Strengthens Board with Appointment of Experienced Biotech Executive Adam Cutler November 23, 2015 Read More » InMed Provides Update on Progress of its Development Program for Epidermolysis Bullosa November 4, 2015 Read More » InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000 November 2, 2015 Read More » InMed Appoints Paul Brennan as President & Chief Executive Officer September 3, 2015 Read More » InMed Commences Development of Proprietary Drug Delivery System September 2, 2015 Read More » InMed Appoints Paul Brennan to the Board of Directors August 25, 2015 Read More » InMed Pharmaceuticals Announces Progress in Orofacial Pain Program August 20, 2015 Read More » InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS) August 6, 2015 Read More » InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline June 3, 2015 Read More » InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS) May 26, 2015 Read More » InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases May 12, 2015 Read More » InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,232,750 May 7, 2015 Read More » InMed Engages Peter Mountford as Strategic Advisor May 5, 2015 Read More » InMed Pharmaceuticals Qualifies for Electronic Trading in the U.S. April 30, 2015 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement of C$250,000 July 19, 2016 Read More »
InMed Announces Appointment of Eric A. Adams as CEO, President and Director June 16, 2016 Read More »
InMed Announces Appointment of William J. Garner, M.D. to its Board of Directors June 13, 2016 Read More »
InMed Pharmaceuticals Provides Strategic Update on its Business Plans, Announces Planned Executive and Board Departures May 4, 2016 Read More »
InMed Strengthens Board with Appointment of Experienced Biotech Executive Adam Cutler November 23, 2015 Read More »
InMed Provides Update on Progress of its Development Program for Epidermolysis Bullosa November 4, 2015 Read More »
InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000 November 2, 2015 Read More »
InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS) August 6, 2015 Read More »
InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline June 3, 2015 Read More »
InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS) May 26, 2015 Read More »
InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases May 12, 2015 Read More »
InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,232,750 May 7, 2015 Read More »